山西证券：首予三生制药(01530)“买入-B”评级 PD-1/VEGF双抗是潜在的肿瘤基石药物

智通财经10-09

智通财经APP获悉，山西证券发布研报称，首予三生制药(01530)“买入-B”评级，预计2025-2027年营收为174.56/107.46/113.35亿元，归母净利润分别为82.89\28.60\31.63亿元，PE为8.1\23.4\21.2。公司有30项在研产品，核心管线PD-1/VEGF双抗SSGJ-707全球权益已授权给辉瑞制药，首付款为15亿美元(14亿美元现金+认购1亿美元股份)，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2574133766?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-10-09 15:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2574133766","market":"hk","top_or_hot":-1,"title":"山西证券：首予三生制药(01530)“买入-B”评级 PD-1/VEGF双抗是潜在的肿瘤基石药物","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，山西证券发布研报称，首予三生制药(01530)“买入-B”评级，预计2025-2027年营收为174.56/107.46/113.35亿元，归母净利润分别为82.89\\28.60\\31.63亿元，PE为8.1\\23.4\\21.2。公司有30项在研产品，核心管线PD-1/VEGF双抗SSGJ-707全球权益已授权给辉瑞制药，首付款为15亿美元(14亿美元现金+认购1亿美元股份)，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1353036.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>山西证券：首予三生制药(01530)“买入-B”评级 PD-1/VEGF双抗是潜在的肿瘤基石药物</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n山西证券：首予三生制药(01530)“买入-B”评级 PD-1/VEGF双抗是潜在的肿瘤基石药物\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-09 15:14 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1353036.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，山西证券发布研报称，首予三生制药(01530)“买入-B”评级，预计2025-2027年营收为174.56/107.46/113.35亿元，归母净利润分别为82.89\\28.60\\31.63亿元，PE为8.1\\23.4\\21.2。公司有30项在研产品，核心管线PD-1/VEGF双抗SSGJ-707全球权益已授权给辉瑞制药，首付款为15亿美元(14亿美元现金+认购1亿美元股份)，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1353036.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"002500","symbol_name":"山西证券","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1353036.html","article_id":"2574133766","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2574133766","pubTimestamp":1759994066,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"公司有30项在研产品，核心管线PD-1/VEGF双抗SSGJ-707全球权益已授权给辉瑞制药，首付款为15亿美元，潜在里程碑付款48亿美元，以及双位数销售梯度分成。山西证券主要观点如下：SSGJ-707是潜在的肿瘤基石药物PD-1疗法是肿瘤治疗的基础方案之一，预计PD-1单抗全球市场在2029年达990亿美元。PD-1/VEGF双抗对抗血管和免疫检查点协同抑制，具比PD-1单抗更优的疗效潜力。SSGJ-707是四价结构的PD-1/VEGF双抗，VEGF存在下对PD-1结合亲和力增强100倍，独特的IgG4 Fc设计有望降低免疫副作用。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"002500":"山西证券","01530":"三生制药","PD":"PagerDuty, Inc."},"translate_title":"Shanxi Securities: First gave 3SBio (01530) a \"Buy-B\" rating PD-1/VEGF dual antibody is a potential cornerstone drug for tumors","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PD":1.5,"01530":1.5,"002500":1.5},"content_text":"智通财经APP获悉，山西证券发布研报称，首予三生制药(01530)“买入-B”评级，预计2025-2027年营收为174.56/107.46/113.35亿元，归母净利润分别为82.89\\28.60\\31.63亿元，PE为8.1\\23.4\\21.2。公司有30项在研产品，核心管线PD-1/VEGF双抗SSGJ-707全球权益已授权给辉瑞制药，首付款为15亿美元(14亿美元现金+认购1亿美元股份)，潜在里程碑付款48亿美元，以及双位数销售梯度分成。山西证券主要观点如下：SSGJ-707是潜在的肿瘤基石药物PD-(L)1疗法是肿瘤治疗的基础方案之一，预计PD-(L)1单抗全球市场在2029年达990亿美元。PD-1/VEGF双抗对抗血管和免疫检查点协同抑制，具比PD-(L)1单抗更优的疗效潜力。SSGJ-707是四价结构的PD-1/VEGF双抗，VEGF存在下对PD-1结合亲和力增强100倍，独特的IgG4 Fc设计有望降低免疫副作用。SSGJ-707临床疗效和安全性优异，在NSCLC、CRC疗效突出，10mg/kg SSGJ-707单药在NSCLC≥3级TRAEs为23.5%，TARE导致的停药为2.9%。辉瑞拥有多特异性抗体临床开发经验、多种实体瘤的商业化能力、以及可联用的ADC。SSGJ-707在中国NSCLCIII期临床，结直肠癌、妇科肿瘤等临床也在推进。SSGJ-707全球临床由辉瑞主持，拟联合ADC等药物治疗肺癌、肠道肿瘤、泌尿肿瘤等，全球潜在治疗人群约300万人(PD-1疗法为140万人)，美国达35万人，有望使潜在BIC的SSGJ-707成为肿瘤基石药物。SSGJ-707单药、联用化疗在一线NSCLCII期临床展现突破性ORR疗效PD-(L)1单药在PD-1低表达的NSCLC应答率有限，而SSGJ-707在低PD-L1表达NSCLC临床有良好疗效。一线PD-L1阳性无EGFR/ALK突变的NSCLC中(n=34)，SSGJ-707单药治疗cORR为64.7%，PD-L1TPS1-49%、≥50%的ORR为62%、77%。在一线无EGFR/ALK突变NSCLC中，SSGJ-707联用化疗治疗鳞状NSCLC、非鳞状NSCLC的ORR分别为81.3%、58.3%。SSGJ-707单药在后线CRCII期临床展现突破性ORR疗效PD-(L)1单药在MSS的CRC应答率有限，而SSGJ-707单药在后线CRC有良好的ORR疗效。≥三线RASm或BRAFm non-MSI-H/pMMR结直肠癌中，SSGJ-707治疗ORR为33.3%。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2574133766","isCrawlerRequest":true}